EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Prodrug Strategies in Atherosclerosis: Targeted Delivery and Therapeutic Advances

Elaheh Mirhadi, Wael Almahmeed, Prashant Kesharwani iD, Amirhossein Sahebkar iD

Cardiovascular Therapeutics · 2026-01 · 2026 (1)

DOI: 10.1155/cdr/5159097 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Therapeutics, online erschienen am 17.08.2026. Verfasst von Elaheh Mirhadi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran, mums.ac.ir. Hauptthemen laut MEDLINE: Prodrugs, Atherosclerosis, Cardiovascular Agents, Anti-Inflammatory Agents. Die Arbeit nennt 178 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atherosclerosis is an advancing and complex vascular condition primarily associated with sustained inflammatory responses, oxidative imbalance, and disruptions in lipid homeostasis. These pathological features render it a major contributor to the global burden of cardiovascular disease, encompassing both morbidity and mortality. Traditional treatment modalities, including statins, angiotensin‐converting enzyme inhibitors, PCSK9 inhibitors and surgical procedures, frequently encounter limitations due to inefficient pharmacokinetic profiles, insufficient targeting of pathological sites and widespread adverse effects. To address these therapeutic shortcomings, prodrug and nano‐prodrug technologies have gained recognition as innovative systems capable of enabling site‐specific and stimuli‐activated therapeutic delivery in atherosclerotic disease management. This review discusses ROS‐responsive prodrugs, biomimetic nano‐prodrug platforms, and multifunctional theranostic nanotechnologies as alternative approaches for advanced atherosclerosis treatment. These systems enable targeted drug activation in oxidative plaque environments, improve pharmacokinetics, and enhance lesion‐specific delivery via mechanisms such as VCAM‐1 targeting, integrins, and cell membrane cloaking. Notably, in preclinical models nano‐prodrugs have been reported to produce combined therapeutic effects by modulating lipid metabolism, reducing inflammation, and preventing foam cell formation, whereas theranostic platforms have enabled real‐time monitoring of treatment response in animals. No nano‐prodrug platform for atherosclerosis has yet been evaluated in humans. Despite progress, key barriers to clinical translation remain, including poor scalability and reproducibility of nanomaterials, patient variability in plaque biology, limited long‐term safety data, and regulatory challenges for complex nanosystems. Future advances will require biomarker‐guided patient selection, robust clinical validation, multistimuli‐responsive designs, and well‐defined regulatory standards. Overcoming these issues is vital for integrating nano‐prodrug technologies into precision atherosclerosis therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsAtherosclerosisCardiovascular AgentsAnti-Inflammatory AgentsHumansAnimalsPlaque, AtheroscleroticOxidative StressReactive Oxygen SpeciesTheranostic NanomedicineNanoparticle Drug Delivery System

Stichwörter der Autor:innen

atherosclerosisinflammationlipid metabolismoxidative stressprodrug

Substanzen

ProdrugsCardiovascular AgentsReactive Oxygen SpeciesAnti-Inflammatory AgentsNanoparticle Drug Delivery System

Autor:innen und Institutionen

  • Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran, mums.ac.ir.
  • Heart and Vascular Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE, clevelandclinicabudhabi.ae.
  • Next-Generation Translational Nanomedicine Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, Madhya Pradesh, India.
  • University Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, India, chandigarhuniversity.ac.in.
  • Centre for Research Impact and Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India, chitkara.edu.in.
  • Applied Biomedical Research Center, Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran, mums.ac.ir.

ORCID-Profile: Prashant Kesharwani, Amirhossein Sahebkar

Zitieren

APA

Mirhadi, E., Almahmeed, W., Kesharwani, P., & Sahebkar, A. (2026). Prodrug Strategies in Atherosclerosis: Targeted Delivery and Therapeutic Advances. Cardiovascular Therapeutics, 2026(1). https://doi.org/10.1155/cdr/5159097

Vancouver

Mirhadi E, Almahmeed W, Kesharwani P, Sahebkar A. Prodrug Strategies in Atherosclerosis: Targeted Delivery and Therapeutic Advances. Cardiovascular Therapeutics. 2026;2026(1). doi:10.1155/cdr/5159097

BibTeX
@article{Mirhadi2026,
  author = {Mirhadi, Elaheh and Almahmeed, Wael and Kesharwani, Prashant and Sahebkar, Amirhossein},
  title = {Prodrug Strategies in Atherosclerosis: Targeted Delivery and Therapeutic Advances},
  journal = {Cardiovascular Therapeutics},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/cdr/5159097}
}
Kostenlos starten →